A61K31/717

Tamper resistant pharmaceutical formulations
11576974 · 2023-02-14 · ·

Disclosed in certain embodiments is a solid oral dosage form comprising a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse.

Tamper resistant pharmaceutical formulations
11576974 · 2023-02-14 · ·

Disclosed in certain embodiments is a solid oral dosage form comprising a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse.

Cognitive function improving agent

Provided are a cognitive function improving agent effective for improving cognitive function such as memory and learning ability, and a method for evaluating or selecting the cognitive function improving agent. The cognitive function improving agent comprises a GIP function inhibitor as an active ingredient.

Cognitive function improving agent

Provided are a cognitive function improving agent effective for improving cognitive function such as memory and learning ability, and a method for evaluating or selecting the cognitive function improving agent. The cognitive function improving agent comprises a GIP function inhibitor as an active ingredient.

ANTIMICROBIAL COMPOSITIONS
20230028624 · 2023-01-26 ·

The invention provides antimicrobial compositions comprising charged cellulose nanofibrils dispersed in an aqueous solution having a dissolved oxygen content of at least 20 mg/L, preferably from 20 to 100 mg/L. The cellulose nanofibrils may have an increased surface charge due to their carboxylic acid content which contributes to their antimicrobial properties. In particular, the carboxylic acid content may be at least about 1000 μmol/g cellulose, preferably at least about 1400 μmol/g cellulose. The compositions are suitable for use in the treatment of wounds, in particular chronic wounds.

ANTIMICROBIAL COMPOSITIONS
20230028624 · 2023-01-26 ·

The invention provides antimicrobial compositions comprising charged cellulose nanofibrils dispersed in an aqueous solution having a dissolved oxygen content of at least 20 mg/L, preferably from 20 to 100 mg/L. The cellulose nanofibrils may have an increased surface charge due to their carboxylic acid content which contributes to their antimicrobial properties. In particular, the carboxylic acid content may be at least about 1000 μmol/g cellulose, preferably at least about 1400 μmol/g cellulose. The compositions are suitable for use in the treatment of wounds, in particular chronic wounds.

ANTIMICROBIAL COMPOSITIONS
20230028624 · 2023-01-26 ·

The invention provides antimicrobial compositions comprising charged cellulose nanofibrils dispersed in an aqueous solution having a dissolved oxygen content of at least 20 mg/L, preferably from 20 to 100 mg/L. The cellulose nanofibrils may have an increased surface charge due to their carboxylic acid content which contributes to their antimicrobial properties. In particular, the carboxylic acid content may be at least about 1000 μmol/g cellulose, preferably at least about 1400 μmol/g cellulose. The compositions are suitable for use in the treatment of wounds, in particular chronic wounds.

DEEP PENETRATING TOPICAL CANNABINOID COMPOSITIONS AND METHODS FOR TREATING MUSCULOSKELETAL INFLAMMATION AND PAIN

Topical compositions comprising cannabinoids in combination with one or more humectants and one or more penetration enhancers are provided. Also provided are methods comprising applying a topical cannabinoid composition provided herein to the skin areas of a subject affected by inflammation and/or pain associated with musculoskeletal disease or condition and uses of a topical cannabinoid formulation provided herein for the treatment of inflammation and/or pain associated with musculoskeletal disease or condition in a subject.

DEEP PENETRATING TOPICAL CANNABINOID COMPOSITIONS AND METHODS FOR TREATING MUSCULOSKELETAL INFLAMMATION AND PAIN

Topical compositions comprising cannabinoids in combination with one or more humectants and one or more penetration enhancers are provided. Also provided are methods comprising applying a topical cannabinoid composition provided herein to the skin areas of a subject affected by inflammation and/or pain associated with musculoskeletal disease or condition and uses of a topical cannabinoid formulation provided herein for the treatment of inflammation and/or pain associated with musculoskeletal disease or condition in a subject.

ADHESION-PREVENTING AGENT AND METHOD FOR PREVENTING ADHESION USING SAME

Provided are an adhesion preventing agent and an adhesion preventing method using the same. Specifically, provided are an adhesion preventing agent, including at least one anionized nanomaterial selected from the group consisting of anionized nanocellulose and anionized nanochitin, and an adhesion preventing method using the adhesion preventing agent.